Oxidative stress in ulcerative colitis: An old concept but a new concern

Free Radical Research

Volumn 46, Issue 11, 2012, Pages 1339-1345

  Jena, Gopabandhu ^a   Trivedi, Priyanka Pushkarbhai ^a   Sandala, Balanarsimha ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Carcinogenesis; DNA damage; Oxidative; Stress; Ulcerative colitis

Indexed keywords

ANTIOXIDANT; C REACTIVE PROTEIN; CALGRANULIN; CATALASE; DEXTRAN SULFATE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LACTOFERRIN; MYELOPEROXIDASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NF E2;

ANEMIA; ARTHRITIS; CARCINOGENESIS; COLORECTAL CANCER; DIARRHEA; DIGESTIVE TRACT ENDOSCOPY; DNA DAMAGE; EDEMA; EFFECTOR CELL; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; ENZYME BLOOD LEVEL; EYE DISEASE; GENE EXPRESSION; HEPATOBILIARY SYSTEM CANCER; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; INTESTINE ULCER; KNOCKOUT MOUSE; LIVER DISEASE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; RASH; RECTUM CARCINOMA; REGULATORY T LYMPHOCYTE; REVIEW; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DNA DAMAGE; HUMANS; OXIDATIVE STRESS;

EID: 84867520629     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2012.717692     Document Type: Review

References (98)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
2. Rodriguez-Bores L, Fonseca GC, Villeda MA, Yamamoto-Furusho JK. Novel genetic markers in infl ammatory bowel disease. World J Gastroenterol 2007; 13: 5560-5570.
3. Abraham C, Cho J. Mechanisms of disease: infl ammatory bowel disease. N Engl J Med 2009; 361: 2066-2078.
4. The Economic Costs of Crohn's Disease and Ulcerative Colitis, 2007 [cited 2007 9th June]. Available from: http://www.crohnsandcolitis. com.au/content/Final-IBD-report-9-June.pdf.
5. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 2011; 11: 9-20.
6. Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of infl ammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007; 52: 2015-2021.
7. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003; 24: 353-362.
8. Westbrook AM, Wei B, Braun J, Schiestl RH. Intestinal mucosal infl ammation leads to systemic genotoxicity in mice. Cancer Res 2009; 69: 4827-4834.
9. Westbrook AM, Wei B, Braun J, Schiestl RH. Intestinal infl ammation induces genotoxicity to extraintestinal tissues and cell types in mice. Int J Cancer 2011; 129: 1815-1825.
10. Montrose DC, H orelik NA, M adigan JP, S toner GD, Wang LS, Bruno RS, et al. Anti-infl ammatory effects of freeze-dried black raspberry powder in ulcerative colitis. Carcinogenesis 2011; 32: 343-350.
11. Xavier RJ, P odolsky DK. U nravelling the pathogenesis of infl ammatory bowel disease. Nature 2007; 448: 427-434.
12. Rothfuss K S, Stange E F, Herrlinger K R. E xtraintestinal manifestations and complications in infl ammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-4831.
13. Eaden JA, Abrams KR, Mayberry JF. T he risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
14. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of populationbased cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645.
15. Bernstein CN, B lanchard JF, Kliewer E, Wajda A. Cancer risk in patients with infl ammatory bowel disease: a population-based study. Cancer 2001; 91: 854-862.
16. Xie J, I tzkowitz SH. Cancer in infl ammatory bowel disease. World J Gastroenterol 2008; 14: 378-389.
17. Hamouda HE, Z akaria SS, I smail SA, K hedr MA, M ayah WW. p53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia. World J Gastroenterol 2011; 17: 2417-2423.
18. Wu CC, C hen JS, W u WM, L iao TN, C hu P, L in SH, et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant 2005; 20: 1134-1139
19. Yong SL, Eiznhamer D, K eshavarzian A. G lutathione content of colonic mucosa (evidence for oxidative damage in active ulcerative colitis). Dig Dis Sci 1998; 43: 1088-1095.
20. Morgenstern I, Raijmakers MTM, Peters WHM, Hoensch H, Kirch W. Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with infl ammatory bowel disease. Dig Dis Sci 2003; 48: 2083-2090.
21. Bruwer M, Schmid KW, Metz KA, Krieglstein CF, Senninger N, Schurmann G. Increased expression of metallothionein in infl ammatory bowel disease. Infl amm Res 2001; 50: 289-293.
22. Soussi T. p 53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60: 1777-1788.
23. El-Sayed ZA, Farag DH, Eissa S. T umor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases. Pedtr Allergy Immunol 2003; 14: 229-233.
24. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of infl amed intestinal mucosa. Gastroenterology 1998; 115: 357-369.
25. Schreiber S, Nikolaus S, Hampe J. A ctivation of nuclear factor kappa B infl ammatory bowel disease. Gut 1998; 42: 477-484.
26. Andresen L, J orgensen VL, Perner A, H ansen A, E ugen-Olsen J, Rask-Madsen J. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 2005; 54: 503-509.
27. Neurath MF, F uss I, S ch ür mann G, Pettersson S, A rnold K, Müller-Lobeck H, et al. Cytokine gene transcription by NFkappa B family members in patients with infl ammatory bowel disease. Ann N Y Acad Sci 1998; 859: 149-159.
28. Schreiber S, Nikolaus S, Hampe J. A ctivation of nuclear factor kB in infl ammatory bowel disease. Gut 1998; 42: 477-484.
29. Neurath MF, Pettersson S, Zum Buschenfelde KHM, S trober W. Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998-1004.
30. Maccarrone M, Meloni C, Manca-di-Villahermosa S, Cococcetta N, Casciani CU, Finazzi-Agro A, Taccone-Gallucci M. Vitamin E suppresses 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kidney Dis 2001; 37: 964-969.
31. Pathak S K, S harma R A, S teward W P, Mellon J K, G riffi ths TR, Gescher AJ. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer 2005; 41: 61-70.
32. Terra VA, S ouza-Neto FP, Pereira RC, D a Silva T N, R amalho LN, Luiz RC, et al. Nitric oxide is responsible for oxidative skin injury and modulation of cell proliferation after 24h of UVB exposure. Free Radic Res 2012; 46: 872-882.
33. Khor TO, Huang MT, Kwon K H, Chan J Y, R eddy B S, K ong AN. Nrf2-defi cient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 2006; 66: 11580-11584.
34. Okada Y, T suzuki Y, M iyazaki J, M atsuzaki K, H okari R, K omoto S, et al. PropionibacteriuMFreudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial fl ora and lymphocyte homing. Gut 2006;:681-688.
35. Turner JR. M olecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006; 169: 1901-1909.
36. Habtezion A, Toivola D M, B utcher E C, O mary M B. K eratin-8-defi cient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment. J Cell Sci 2005; 118: 1971-1980.
37. Kaser A, L ee AH, F ranke A, G lickman JN, Z eissig S, T ilg H, et al. XBP1 links ER stress to intestinal infl ammation and confers genetic risk for human infl ammatory bowel disease. Cell 2008; 134: 743-756.
38. Elson CO, Cong Y, McCracken V J, Dimmitt R A, Lorenz R G, Weaver CT. Experimental models of infl ammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005; 206: 260-276.
39. Ferguson LR. C hronic infl ammation and mutagenesis. M utat Res 2010; 690: 3-11.
40. Pavlick KP, L aroux FS, F useler J, W olf RE, G ray L, H offman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in infl ammatory bowel disease. Free Radic Biol Med 2002; 33: 311-322.
41. Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol 2005; 11: 2371-2384.
42. Grisham MB. R ole of reactive oxygen metabolites in infl ammatory bowel disease. Curr Opin Gastroenterol 1993; 9: 971-980.
43. Fan H, Sun B, Gu Q, Lafond-Walker A, C ao S, B ecker L C. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 2002; 282: 1778-1786.
44. Konishi H, Tanaka M, T akemura Y, M atsuzaki H, O no Y, Kikkawa U, Nishizuka Y. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci USA 1997; 94: 11233-11237.
45. Morel Y, B arouki R. R epression of gene expression by oxidative stress. Biochem J 1999; 342: 481-496.
46. Schreck R, A lbermann K, B aeuerle PA. N uclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 1992; 17: 221-237.
47. Atreya R, Neurath MF. I nvolvement of IL-6 in the pathogenesis of infl ammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005; 28: 187-196.
48. Libermann TA, B altimore D. A ctivation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10: 2327-2334.
49. Mudter J, N eurath MF. I l-6 signaling in infl ammatory bowel disease: pathophysiological role and clinical relevance. Infl amm Bowel Dis 2007; 13: 1016-1023.
50. Littman DR, R udensky A Y. T h17 and regulatory T cells in mediating and restraining infl ammation. Cell 2010; 140: 845-858.
51. Ahern PP, I zcue A, M aloy KJ, P owrie F. T he interleukin-23 axis in intestinal infl ammation. Immunol Rev 2008; 226: 147-159.
52. Ohshima H, T atemichi M, S awa T. C hemical basis of infl ammation induced carcinogenesis. Arch Biochem Biophys 2003; 417: 3-11.
53. Sawa T, O hshima H. N itrative DNA damage in infl ammation and its possible role in carcinogenesis. Nitric Oxide 2006; 14: 91-100.
54. Kaneko K, A kuta T, S awa T, K im HW, F ujii S, O kamoto T, et al. Mutagenicity of 8-nitroguanosine, a product of nitrative nucleoside modifi cation by reactive nitrogen oxides, in mammalian cells. Cancer Lett 2008; 262: 239-247.
55. Kondo S, T oyokuni S, I wasa Y, Tanaka T, O nodera H, H iai H, Imamura M. Persistent oxidative stress in human colorectal c arcinoma, but not in adenoma. Free Radic Biol Med 1999; 27: 401-410.
56. Peluso M, M unnia A, P iro S, J edpiyawongse A, S angrajrang S, Giese RW, et al. Fruit and vegetable and fried food consumption and 3-(2-deoxy-beta-D- erythro-pentafuranosyl)pyrimido[1,2-alpha] purin-10(3H)-one deoxyguanosine adduct formation. Free Radic Res 2012; 46: 85-92.
57. Gushima M, H irahashi M, M atsumoto T, F ujita K, F ujisawa R, Mizumoto K, et al. Altered expression of MUTYH and an increase in 8-hydroxydeoxyguanosine are early events in ulcerative colitis-associated carcinogenesis. J Pathol 2009; 219: 77-86.
58. Westbrook AM, W ei B, B raun J, S chiestl R H. M ore damaging than we think: systemic effects of intestinal infl ammation. Cell Cycle 2009; 8: 2482-2483.
59. Memon M I, M emon B, M emon M A. H epatobiliary manifestations of infl ammatory bowel disease. HPB Surg 2000; 11: 363-371.
60. Trivedi P P, J ena G B. D extran sulfate sodium-induced ulcerative colitis leads to increased hematopoiesis and induces both local as well as systemic genotoxicity in mice. Mutat Res 2012; 744: 172-183.
61. G oldman M, W illems F. O xidative stress upregulates IL-8 and TNF-alpha synthesis by human dendritic cells. Eur J Immunol 1998; 28: 3886-3890.
62. Barrie A, R egueiro M. B iologic therapy in the management of extraintestinal manifestations of infl ammatory bowel disease. Infl amm Bowel Dis 2007; 13: 1424-1429.
63. Dechakhamphu S, Y ongvanit P, N air J, P inlaor S, S itthithaworn P, Bartsch H. High excretion of etheno adducts in liver fl ukeinfected patients: protection by praziquantel against DNA damage. Cancer Epidemiol Biomarkers Prev 2008; 17: 1658-1664.
64. Meerang M, N air J, S irankapracha P, T hephinlap C, S richairatanakool S, Arab K, et al. Accumulation of lipid peroxidationderived DNA lesions in iron-overloaded thalassemic mouse livers: comparison with levels in the lymphocytes of thalassemia patients. Int J Cancer 2009; 125: 759-766.
65. Liao J, S eril DN, L u GG, Z hang M, T oyokuni S, Y ang A L, Y ang GY. Increased susceptibility of chronic ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 defi cient mice. Mol Carcinog 2008; 47: 638-646.
66. Hofseth LJ, K han MA, A mbrose M, N ikolayeva O, X u-Welliver M, Kartalou M, et al. The adaptive imbalance in base excisionrepair enzymes generates microsatellite instability in chronic infl ammation. J Clin Invest 2003; 112: 1887-1894.
67. Inokuma T, H araguchi M, F ujita F, T ajima Y, K anematsu T. Oxidative stress and tumor progression in colorectal cancer. Hepatogastroenterology 2009; 56: 343-347.
68. Chang D, Wang F, Z hao Y S, P an HZ. E valuation of oxidative stress in colorectal cancer patients. Biomed Environ Sci 2008; 21: 286-289.
69. Cerda S, W eitzman SA. I nfl uence of oxygen radical injury on DNA methylation. Mutat Res 1997; 386: 141-152.
70. Counts J L, M cClain R M, G oodman J I. C omparison of effect of tumor promoter treatments on DNA methylation status and gene expression in B6C3F1 and C57BL/6 mouse liver and in B6C3F1 mouse liver tumors. Mol Carcinog 1997; 18: 97-106.
71. Herman JG, Latif F, Weng Y, L erman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704.
72. Herman JG, M erlo A, M ao L, L apidus RG, I ssa JP, D avidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-4530.
73. Hinoue T, W eisenberger DJ, L ange CP, S hen H, B yun HM, V an Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-282.
74. Nabilsi N H, B roaddus R R, L oose D S. D NA methylation inhibits p53-mediated survivin repression. Oncogene 2009; 28: 2046-2050.
75. Ohtani-Fujita N, F ujita T, A oike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993; 8: 1063-1067.
76. Ha P K, C alifano J A. P romoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006; 7: 77-82.
77. Lim SO, Gu JM, Kim MS, Kim HS, Park YN, Park CK, et al. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 2008; 135: 2128-2140.
78. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profi les of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005; 18: 412-420.
79. Fagerhol MK. S urrogate markers of intestinal infl ammation are predictive of relapse in patients with infl ammatory bowel disease. Gastroenterology 2000; 119: 15-22.
80. Masoodi I, T ijjani B M, Wani H, H assan N S, K han A B, H ussain S. Biomarkers in the management of ulcerative colitis: a brief review Ger Med Sci 2011; Article in press.
81. Bischoff S C, G rabowsky J, Manns M P. Quantifi cation of infl ammatory mediators in stool samples of patients with infl ammatory bowel disorders and controls. Dig Dis Sci 1997; 42: 394-403.
82. Sugi K, Saitoh O, Hirata I, Katsu K. F ecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91: 927-934.
83. Erbayrak M, T urkay C, E raslan E, C etinkaya H, K asapoglu B, Bektas M. The role of fecal calprotectin in investigating infl ammatory bowel diseases. Clinics 2009; 64: 421-425.
84. Golikov P. A novel biomarker for diagnosis of ulcerative colitis and colon cancer, [cited: 2003]. Available from: www.umdnj.edu/resrhweb/patents/for- licensing/diagnostics/01-08-Das-A-b-Colitis.pdf.
85. Bousvaros A, S ylvester F, K ugathasan S, S zigethy E, F iocchi C, Colletti R, et al. Challenges in pediatric infl ammatory bowel disease. Infl amm Bowel Dis 2006; 12: 885-913.
86. Dong WG, Mei Q, Yu JP, Xu JM, Xiang L, Xu Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003; 9: 1307-1311.
87. Kolgazi M, J ahovic N, Y uksel M, E rcan F, A lican I. A lpha-lipoic acid modulates gut infl ammation induced by trinitrobenzene sulfonic acid in rats. J Gastroenterol Hepatol 2007; 22: 1859-1865.
88. Mirbagheri SA, Nezami BG, Assa S, Hajimahmoodi M. R ectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. World J Gastroenterol 2008; 14: 5990-5995.
89. Trivedi PP, K ushwaha S, T ripathi DN, J ena GB. Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. Cardiovasc Toxicol 2011; 11: 215-225.
90. Trivedi PP, Tripathi D N, Jena GB. Hesperetin protects testicular toxicity of doxorubicin in rat: role of NFkappaB, p38 and caspase-3. Food Chem Toxicol 2011; 49: 838-847.
91. Dave M, L oftus EV Jr. M ucosal healing in infl ammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (NY) 2012; 8: 29-38.
92. Loguercio C, D'Argenio G, Delle Cave M, Cosenza V, Della Valle N, Mazzacca G, Del Vecchio Blanco C. Glutathione supplementation improves oxidative damage in experimental colitis. Dig Liver Dis 2003; 35: 635-641.
93. Arafa H M, Hemeida RA, El-Bahrawy AI, Hamada FM. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol 2009; 47: 1311-1317.
94. Yao J, Wang JY, Liu L, Li YX, Xun AY, Zeng WS, et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch Med Res 2010; 41: 288-294.
95. Chojnacki C, W isniewska-Jarosinska M, Walecka-Kapica E, Klupinska G, Jaworek J, Chojnacki J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 2011; 62: 327-334.
96. Hanai H, I ida T, T akeuchi K, Watanabe F, M aruyama Y, A ndoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4: 1502-1506.
97. Meira LB, B ugni JM, G reen SL, L ee C W, P ang B, B orenshtein D, et al. DNA damage induced by chronic infl ammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118: 2516-2525.
98. Grimble RF Nutritional antioxidants and the modulation of infl ammation: theory and practice. New Horiz 1994; 2: 175-185